DoD Lupus, Idea Award

The Lupus Research Program Idea Award is a federal funding opportunity administered by the Defense Health Agency Contracting Activity through the Congressionally Directed Medical Research Programs as part of the Lupus Research Program. The opportunity is designed to support innovative, high-risk and high-reward research that may lead to critical discoveries or major advancements related to lupus. Congress initiated the Lupus Research Program in 2017 to advance research with significant scientific merit and meaningful impact for individuals affected by lupus, including Service Members, Veterans, their Families and the general public. The program vision is to cure lupus through partnerships among scientists, clinicians and people living with lupus, while its mission focuses on improving understanding, prevention, diagnosis, treatment and quality of life outcomes associated with lupus disease. The Idea Award mechanism specifically supports projects that propose novel hypotheses, creative research paradigms or entirely new investigative directions in lupus research rather than incremental advances to existing projects. Applications are required to address at least one fiscal year 2026 focus area. These focus areas include understanding lupus disease heterogeneity, biological mechanisms of disease, pathobiology of end organ injury, quality of life improvements for individuals living with lupus and studies involving genetic and epigenetic components of lupus disease. The program encourages multidisciplinary collaboration and the use of computational methods, data science and innovative technologies. Preliminary data are permitted but not required, making the mechanism especially attractive for early-stage and exploratory concepts. Clinical trials are explicitly prohibited under this funding opportunity. Eligibility is broad and includes domestic and international organizations, nonprofit and for-profit entities, public and private institutions and intramural and extramural Department of War organizations. Independent investigators and mentored investigators, including postdoctoral fellows or equivalent researchers who have received terminal degrees, are eligible to serve as Principal Investigators if affiliated with eligible organizations. Applications submitted by mentored investigators require a mentorship statement and supporting mentor documentation. An investigator may only serve as Principal Investigator on one fiscal year 2026 Lupus Research Program Idea Award application. Cost sharing is not required. Awards are issued to organizations rather than individuals. The funding opportunity anticipates approximately five awards using an estimated total program allocation of approximately 1.5 million dollars. Each award may request up to 300000 dollars in total costs with a maximum performance period of two years. Indirect costs may be included in accordance with negotiated indirect cost agreements, and all direct and indirect costs associated with subawards or contracts must be included within the total direct costs of the primary award. Direct costs may not include clinical trial expenses. Awards funded through fiscal year 2026 appropriations are expected to be issued no later than September 30, 2027, and available federal funds will expire for use on September 30, 2032. The application process consists of a mandatory two-step submission process involving both a pre-application and a full application. Applicants must first submit a Letter of Intent through the Electronic Biomedical Research Application Portal by July 29, 2026. The Letter of Intent is limited to one page and must briefly describe the proposed research and identify the applicable focus area. Following successful pre-application submission, applicants may submit full applications through Grants.gov if they are extramural organizations or through eBRAP if they are intramural Department of War organizations. Full applications are due August 19, 2026, with an application verification deadline of August 24, 2026. Required application materials include a project narrative, technical abstract, lay abstract, statement of work, innovation statement, impact statement and supporting documentation. Additional attachments may include mentorship statements, animal research plans, transition plans, commercialization strategies and research sharing plans depending on the proposed project scope. Applications are reviewed through a two-tier review process consisting of peer review and programmatic review. Peer review evaluates scientific merit based on research strategy and feasibility, innovation, impact and transition planning. Additional considerations include personnel qualifications, research sharing plans, budget appropriateness and institutional environment. Programmatic review considers peer review outcomes alongside program priorities, portfolio composition, innovation and overall impact. The highest-scoring applications are not automatically funded because final recommendations depend on programmatic balance and strategic priorities. Applicants are notified of funding recommendations through eBRAP approximately six weeks after programmatic review, and successful applicants subsequently enter negotiations with authorized grants officials. The funding opportunity emphasizes rigorous study design, reproducibility and inclusion considerations, including strategies for considering sex as a biological variable and inclusion of women and minorities in applicable research. Applicants proposing animal research must follow ARRIVE guidelines, while projects involving military or Veterans Affairs populations must document access plans and support agreements. Recipients will be required to submit annual and final technical reports using Research Performance Progress Report standards and may be subject to additional federal compliance and integrity reporting requirements. The funding opportunity is recurring as part of the annual Lupus Research Program portfolio and is identified under Funding Opportunity Number HT942526LRPIA.

Clearly emphasize innovation and explain how the project represents a non incremental advance in lupus research. Explicitly connect the project to at least one FY26 focus area and describe patient impact and quality of life relevance. Strong scientific rationale, rigorous methodology, reproducibility planning and transition planning are important review criteria.